📇 Rhumatologue · CHAMBERY CEDEX · (73) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
151.5 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHMS - SITE CHAMBERY MCO
PL LUCIEN BISET BP 31125, 73011 CHAMBERY CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of neuro-oncology · 2017
European journal of nuclear medicine and molecular imaging · 2018
Hematological oncology · 2015
AbstractRituximab was approved in France in 2004, following randomized trials that demonstrated efficacy in newly diagnosed high tumour burden follicular lymphoma (FL). This retrospective study compared the management and outcome of FL in unselected patients treated in a single institution before and after rituximab approval. Two hundred and forty‐seven adult patients were referred with first‐line FL between 1996 and 2010 and are included in this study. The 103 pre‐rituximab patients comprising cohort 1 were diagnosed between January 1996 and December 2003; cohort 2 includes the 144 patients diagnosed after the approval of rituximab between January 2004 and December 2010. Baseline clinical and biological data, type of therapy, treatment response, progression‐free survival (PFS) and overall survival (OS) rates were compared. There were no statistically significant differences between the two cohorts with respect to baseline clinical and disease characteristics, including FL International Prognostic Index score. The major difference between the two cohorts is the use of rituximab in first line. Seventy‐one per cent of patients in cohort 2 received rituximab (19% alone, 52% with chemotherapy) versus 10% in cohort 1 (2% alone, 8% with chemotherapy;p < 0.0001). The objective response rate (ORR) was significantly higher for cohort 2 (ORR84% compared with 72% for cohort 1;p = 0.03). The PFS and OS rates were also significantly better: 3‐yearPFS72% [95% confidence interval (CI) 64–80%] versus 55% (95% CI 45–64%),p = 0.0039 and 3‐yearOS98% (95% CI 94–99%) versus 83% (95% CI 74–90%),p = 0.0007. Effect of period of study is significant when using multivariate analysis on PFS and OS and lactate dehydrogenase level (PFS and OS) and age (OS). These data from everyday practice confirm the benefit for patients with FL treated in the last decade through availability of rituximab in first line used alone or in association with various chemotherapy regimens. Copyright © 2014 John Wiley & Sons, Ltd.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of neuro-oncology · 2017 · Journal Article
Houillier C, Ghesquières H, Chabrot C, Soussain C, et al.
Hematological oncology · 2015 · Journal Article
Nicolas-Virelizier E, Ségura-Ferlay C, Ghesquières H, Chassagne-Clément C, et al.
European journal of nuclear medicine and molecular imaging · 2018 · Journal Article
Al Tabaa Y, Tchernonog E, Faurie P, Cottereau AS, et al.
La Revue de medecine interne · 2010 · Case Reports
Faurie P, Pérard L, Hot A, Desmurs-Clavel H, et al.
Journal of neuro-oncology · 2017 · Journal Article
Houillier C, Ghesquières H, Chabrot C, Soussain C, et al.
Journal of adolescent and young adult oncology · 2019 · Journal Article
Dony A, Belhabri A, Bertrand Y, Sebban C, et al.